Ocular Nanoformulations
Non-invasive eye drops and implants for AMD, glaucoma, dry eye, and ocular inflammation.
A comprehensive ocular drug delivery portfolio designed to make non-invasive treatment viable for conditions that currently demand invasive interventions.
Highlights include high-dose atorvastatin SLN ocular drops for age-related macular degeneration with demonstrated retinal-protective effects (Indian patent granted; Singapore patent filed for a related technology); cannabidiol-loaded polymeric micelles for uveitis and ocular inflammation (Indian patent and PCT filed); bimatoprost nanovesicular eye drops for long-term glaucoma relief; and novel lipo-polymeric drops for dry eye.
A cutting-edge 2D-electrospun nanofiber ocular insert (patent pending) integrates an anti-VEGF peptide and omega-3-rich active for AMD and corneal neovascularization — offering sustained localised release with superior corneal adhesion, targeting VEGFR-2 signalling to suppress pathological angiogenesis.
Additional platforms cover fluconazole and amphotericin B SLN drops for ocular fungal infections and atorvastatin-CBD nanoparticulate systems for ocular inflammation.
Patents
- 351437 — Ocular formulation (India, granted 2020)
- 341360 — Autoclavable nanovesicular composition (India, granted 2020)
- 336184 — Nanostructured lipidic polymeric pharmaceutical compositions (India, granted 2020)
- IPOS 10202502312X — Formulation for the Treatment of Chronic Retinal Disease (Singapore, filed 2025)